Intrexon Corp (NASDAQ:XON) Expected to Announce Earnings of -$0.24 Per Share

Wall Street brokerages expect Intrexon Corp (NASDAQ:XON) to announce earnings per share of ($0.24) for the current quarter, according to Zacks. Two analysts have made estimates for Intrexon’s earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.27). Intrexon reported earnings per share of ($0.14) during the same quarter last year, which would suggest a negative year over year growth rate of 71.4%. The business is expected to issue its next quarterly earnings results on Thursday, November 14th.

On average, analysts expect that Intrexon will report full-year earnings of ($1.17) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($1.06). For the next year, analysts expect that the business will report earnings of ($0.75) per share, with EPS estimates ranging from ($0.80) to ($0.69). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Intrexon.

Intrexon (NASDAQ:XON) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.05. The firm had revenue of $35.99 million for the quarter, compared to analysts’ expectations of $29.62 million. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. The business’s revenue for the quarter was down 20.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.51) earnings per share.

A number of research analysts have recently commented on XON shares. ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Northland Securities restated a “hold” rating and issued a $10.00 price target on shares of Intrexon in a report on Monday, August 12th. Bank of America cut their price target on shares of Intrexon from $7.00 to $6.00 and set an “underperform” rating on the stock in a report on Friday, August 9th. Finally, BidaskClub cut shares of Intrexon from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Intrexon presently has an average rating of “Hold” and a consensus price target of $17.00.

Shares of NASDAQ XON traded up $0.37 during mid-day trading on Friday, reaching $7.01. The company had a trading volume of 1,176,200 shares, compared to its average volume of 1,240,727. The stock’s 50-day moving average price is $7.49. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.57 and a current ratio of 3.55. The firm has a market cap of $1.08 billion, a PE ratio of -5.12 and a beta of 2.22. Intrexon has a 52 week low of $3.95 and a 52 week high of $19.94.

In related news, SVP Robert F. Walsh III sold 5,007 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $7.76, for a total value of $38,854.32. Following the completion of the sale, the senior vice president now directly owns 33,823 shares of the company’s stock, valued at $262,466.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Randal J. Kirk acquired 483,268 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was acquired at an average cost of $5.24 per share, with a total value of $2,532,324.32. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 1,706,993 shares of company stock valued at $8,319,188 and sold 22,672 shares valued at $173,474. 44.00% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. PFG Advisors lifted its position in shares of Intrexon by 21.7% during the second quarter. PFG Advisors now owns 12,350 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 2,200 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Intrexon by 4.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 58,956 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 2,600 shares during the last quarter. LPL Financial LLC lifted its position in shares of Intrexon by 15.8% during the second quarter. LPL Financial LLC now owns 19,494 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 2,659 shares during the last quarter. First Republic Investment Management Inc. lifted its position in shares of Intrexon by 13.9% during the second quarter. First Republic Investment Management Inc. now owns 41,000 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 5,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Intrexon by 1.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 417,274 shares of the biotechnology company’s stock valued at $3,197,000 after buying an additional 5,612 shares during the last quarter. 70.83% of the stock is owned by institutional investors.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Article: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Intrexon (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.